Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 125 versus BACTOCILL IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 125 versus BACTOCILL IN PLASTIC CONTAINER.
AUGMENTIN '125' vs BACTOCILL IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases, preventing hydrolysis of amoxicillin.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity essential for peptidoglycan cross-linking.
One AUGMENTIN '125' tablet (amoxicillin 125 mg, clavulanate 31.25 mg) orally every 8 hours for mild to moderate infections.
1-2 g intravenously every 4 hours.
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours (prolonged in renal impairment; up to 7-20 hours in anuria). Clavulanate: 0.9-1.2 hours (increased in renal impairment).
30-60 minutes (mean 40 min) in adults with normal renal function; prolonged to 7-10 hours in anuria. Clinical context: dosing interval adjustment required in renal impairment.
Amoxicillin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; clavulanate: ~30-50% excreted unchanged in urine. Small amounts eliminated in bile and feces.
Primarily renal (60-70% unchanged by tubular secretion and glomerular filtration); biliary/fecal excretion accounts for <30%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic